Goodpasture syndrome refers to an anti-glomerular basement membrane (anti-GBM) disease that involves both the lungs and kidneys, often presenting as pulmonary hemorrhage and glomerulonephritis. However, some clinicians may use several terms interchangeably, including anti-glomerular basement membrane disease, Goodpasture syndrome, and Goodpasture disease. The anti-GBM disease is the most specific term, and refers to the presence of renal and pulmonary involvement, along with anti-glomerular basement membrane antibodies. The spectrum of disease may present classically or as glomerulonephritis alone.
Goodpasture syndrome is an eponym named after Ernest Goodpasture, who described this disorder for the first time in 1919. Later the discovery of anti-GBM antibodies led to a better understanding of the pathogenesis of Goodpasture syndrome.
Anti-GBM disease appears to result from environmental insults in a person with a genetic predisposition. At this point, a triggering stimulus has not been identified for the development of anti-glomerular basement membrane antibodies. However, there are certain human leukocyte antigen (HLA) subtypes that have been implicated in conferring increased genetic susceptibility to Goodpasture syndrome, most notably HLA-DR15. The exposure of the alveolar capillaries to these autoantibodies needs an initial insult to the pulmonary vasculature. These environmental factors include:
Anti-GBM disease is a rare disorder. The incidence of the anti-GBM disease is approximately 0,5 to 1.8 cases per million per year in Asian and European populations. It is responsible for 1-5% of all kinds of glomerulopathies. Furthermore, it accounts for 10-20% of crescentic glomerulonephritis.
Goodpasture syndrome is due to circulating autoantibodies directed at the glomerular basement membrane. The resulting crescentic glomerulonephritis is the result of the antigen-antibody complexes that form at the basement membrane. The autoantibodies activate the complement system in the basement membrane causing tissue injury. This binding of autoantibodies can be seen as a linear deposition of immunoglobulins along the basement membrane. The inflammatory response in that area results in the typical picture of glomerulonephritis.
Alveolar basement membrane shares the same collagen target as that of the glomerulus. The main component of the basement membrane is type IV collagen which can be expressed as six different chains, from alpha 1 to alpha 6. Despite the presence of circulating antibodies in anti-glomerular basement membrane disease, pulmonary symptoms are not always observed. An inciting lung injury seems to make pulmonary symptoms more likely.
In a healthy individual, the alveolar endothelium acts as a barrier to the anti-basement membrane antibodies. However, if an insult results in increased permeability of the alveolar capillaries, it leads to the trespassing of autoantibodies which then bind to the basement membrane. The factors that may result in an increased alveolar-capillary permeability include:
In patients where renal and pulmonary involvement raises suspicion of anti-GBM disease, renal biopsy should be considered, which has a better yield as opposed to lung biopsy. Light microscopy will show crescentic glomerulonephritis. Over time, the crescents turn fibrotic, and frank glomerulosclerosis with interstitial fibrosis and tubular atrophy may be appreciated. Immunofluorescence will show the linear deposition of IgG and complement (C3) along the basement membrane. Predominantly, subclass IgG-1 is present.
A kidney biopsy is not only crucial for diagnosis, but the percentage of crescents identified on biopsy confers renal survival prognosis. Lung tissue is typically not sought due to the invasiveness of the procedure and a more difficult immunofixation process for lung tissue. Lung biopsy, when performed, shows extensive hemorrhage with deposition of hemosiderin-laden macrophages within alveolar spaces.
Patients with anti-glomerular basement membrane antibody syndrome will initially present similarly to other forms of rapidly progressive glomerulonephritis with acute renal failure. There are no symptoms specific to the anti-glomerular basement membrane that distinguish it from other diseases causing similar organ dysfunction, and careful and expedient workup must be undertaken for an accurate diagnosis. The pulmonary symptoms are typically present at the time of the initial encounter, or shortly after that. Hemoptysis of varying degrees is typical when there is pulmonary involvement, ranging from serious and life-threatening bleeding to more subtle diffuse hemorrhage that is only apparent on more careful evaluation. It is more typical for younger patients affected by the anti-glomerular basement membrane disease to present with simultaneous renal and pulmonary symptoms (Goodpasture syndrome) and to be critically ill on presentation. Patients over 50 years old tend to present with glomerulonephritis alone and follow a less severe course.
Careful physical examination of patients presenting with finding suspicious for the anti-glomerular basement membrane disease should be done, particularly for other signs such as a purpuric rash. This finding may suggest so-called “double-positive” patients who have concurrent ANCA-associated vasculitis (granulomatosis with polyangiitis).
A kidney biopsy is the gold standard for diagnosis but is not required either to begin treatment or to continue therapy if a biopsy is not feasible. When performed, biopsy provides important information regarding the activity and chronicity of renal involvement that may help guide therapy.
Serologic testing for ELISA assay for circulating anti-GBM antibodies should be done immediately on suspicion of the disease. Specifically, it is essential that the alpha3 NC1 domain area of collagen IV be used as the target in this assay as false positives may be seen in less specific testing. Quantitative titers are followed during treatment phases to guide treatment decisions.
Urinalysis is characteristic and usually demonstrates low-grade proteinuria, gross or microscopic hematuria, and RBC casts.
A complete blood count may reveal anemia secondary to intrapulmonary hemorrhages, and leukocytosis is generally present.
Renal function tests may be deranged secondary to renal dysfunction.
A chest radiograph shows patchy parenchymal opacifications, which are usually bilateral and bibasilar. The apices and costophrenic angles are generally spared.
Pulmonary function tests show elevated diffusing capacity for carbon monoxide (DLCO) secondary to binding of carbon monoxide to intra-alveolar hemoglobin.
Patients presenting with Goodpasture syndrome (both glomerulonephritis and pulmonary hemorrhage) may be critically ill on presentation. Urgent hemodialysis often is needed for standard indications, and intubation for respiratory failure may be necessary. When the diagnosis is being considered, kidney biopsy should be done as soon as the clinical situation allows.
Upon diagnosis, patients should be started on prednisone, cyclophosphamide, and daily plasmapheresis to improve overall mortality in general, and renal survival in particular. If therapy can start before the patient progresses to the point of needing renal replacement therapy, the overall renal prognosis is better. All patients with pulmonary symptoms should be started on combined therapy regardless of their renal status. For patients without pulmonary symptoms in whom renal recovery is very unlikely (i.e., for those that presented with the urgent need for dialysis within the first 72 hours), the risk of plasmapheresis and immunosuppressive may outweigh the benefits. The choice to withhold treatment in these cases remains controversial as the disease has not been well-studied in controlled trials, and it remains difficult to predict who in this group exactly will respond and recover renal function. The overall return of renal function in this group is approximately 8%, yet many clinicians still opt for a trial of aggressive combined therapy at this time.
Typically, daily plasmapheresis is performed until anti-glomerular basement membrane antibodies are undetectable, with steroid and cyclophosphamide continuing after that for 3 to 6 months until full remission is achieved. This can be gauged by checking repeated titers following plasmapheresis, as well as any time new symptoms develop that could be a harbinger of relapse. Overall, relapse remains rare. The starting dose of cyclophosphamide is 2 mg/kg orally, adjusted to keep a white cell count of approximately 5000. Treatment of acute life-threatening alveolar hemorrhage is with IV methylprednisolone pulse therapy 1g/day for 3 days, followed by a tapering dose at 1-1.5 mg/kg orally.
Rituximab has been found to have a role in some studies in which the conclusion was that it led to the undetectable levels of anti-GBM antibodies.
All the pulmonary-renal syndromes that affect the lung and kidney are to be considered in the differentials. These include:
Some patients with Goodpasture syndrome also have ANCAs positive, which makes it difficult to distinguish it from granulomatosis with polyangiitis.
Some IgA-mediated disorders also present with pulmonary-renal syndromes, such as:
Other differential diagnoses include:
With the development of aggressive therapies such as plasmapheresis, corticosteroids, and immunosuppressive agents the prognosis of Goodpasture syndrome has significantly improved. With these therapies, the 5-year survival rate has exceeded 80% and less than 30% of patients require long-term dialysis. However, delayed administration of cyclophosphamide has been found to be associated with a fatal prognosis.
A nephrologist should be consulted for the evaluation of a patient in terms of:
As these patients may present with serious and life-threatening pulmonary complications, a pulmonologist should be consulted to guide therapy.
A surgeon's assistance may also be needed in cases where vascular access is needed for hemodialysis or plasmapheresis.
The prognosis for this spectrum of diseases is overall good, provided the disease is identified efficiently, and treatment started promptly. Overall survival and renal recovery track along with the degree of renal impairment on presentation.
Recurrence is rare but possible, and patients typically do well with recurrent episodes. This is most likely due to heightened clinical suspicion. Treatment in recurrent cases is identical to the initial episode.
Patients that do not recover renal function and remain dependent on renal replacement therapy may qualify for renal transplantation. Anti-glomerular basement membrane antibody titers should be negative for at least six months before transplantation. These patients rarely experience recurrent disease in the current era following transplant, but it has been reported in the literature. It has been theorized that long-term use of immunosuppressive agents aimed at protecting the graft from rejection simultaneously keeps the autoimmune disease from recurring.
Management of Goodpasture syndrome requires careful coordination of several specialties. The involvement of pulmonary/critical care, nephrology, and rheumatology should be sought depending on the spectrum of clinical findings and the severity of the disease. An interprofessional team consisting of nurses, nurse practitioners, physician assistants, and physicians will provide the best results. Transfer to a center capable of providing input from those specialties is advisable. Plasmapheresis, if indicated, should be sought. Initial lab assays should be expedited, and protocols should be put in place for all members of the team are aware of positive test results and can act on them immediately.
|||Diagnosis and classification of Goodpasture's disease (anti-GBM)., Hellmark T,Segelmark M,, Journal of autoimmunity, 2014 Feb-Mar [PubMed PMID: 24456936]|
|||The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity., Phelps RG,Rees AJ,, Kidney international, 1999 Nov [PubMed PMID: 10571772]|
|||Cranfield A,Mathavakkannan S, Goodpasture's disease following extracorporeal shock wave lithotripsy: a case report & literature review. Clinical case reports. 2015 Mar [PubMed PMID: 25838905]|
|||Kluth DC,Rees AJ, Anti-glomerular basement membrane disease. Journal of the American Society of Nephrology : JASN. 1999 Nov [PubMed PMID: 10541306]|
|||Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease., Tang W,McDonald SP,Hawley CM,Badve SV,Boudville NC,Brown FG,Clayton PA,Campbell SB,de Zoysa JR,Johnson DW,, Kidney international, 2013 Mar [PubMed PMID: 23254902]|
|||Goodpasture's disease., Salama AD,Levy JB,Lightstone L,Pusey CD,, Lancet (London, England), 2001 Sep 15 [PubMed PMID: 11567730]|
|||[PubMed PMID: 21207195]|
|||[PubMed PMID: 19364515]|
|||Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome., Kalluri R,Wilson CB,Weber M,Gunwar S,Chonko AM,Neilson EG,Hudson BG,, Journal of the American Society of Nephrology : JASN, 1995 Oct [PubMed PMID: 8589284]|
|||[PubMed PMID: 3892220]|
|||[PubMed PMID: 11388816]|
|||[PubMed PMID: 29503131]|
|||[PubMed PMID: 23352254]|
|||[PubMed PMID: 1317224]|
|||[PubMed PMID: 12597309]|
|||[PubMed PMID: 26812945]|
|||Recurrent Goodpasture's disease., Levy JB,Lachmann RH,Pusey CD,, American journal of kidney diseases : the official journal of the National Kidney Foundation, 1996 Apr [PubMed PMID: 8678069]|
|||KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis., Beck L,Bomback AS,Choi MJ,Holzman LB,Langford C,Mariani LH,Somers MJ,Trachtman H,Waldman M,, American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013 Sep [PubMed PMID: 23871408]|
|||Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy., Sauter M,Schmid H,Anders HJ,Heller F,Weiss M,Sitter T,, Clinical transplantation, 2009 Jan-Feb [PubMed PMID: 19087095]|